☆ 4.7 Meeting Abstract

Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

ANNALS OF ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S507-S507

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.869

Keywords

-

Categories

Oncology

Funding

  1. Amgen Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.